Affimed EPS - Earnings per Share 2014-2024 | AFMDQ
Affimed eps - earnings per share from 2014 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Affimed Annual EPS |
| 2023 |
$-7.67 |
| 2022 |
$-6.37 |
| 2021 |
$-5.68 |
| 2020 |
$-5.71 |
| 2019 |
$-5.60 |
| 2018 |
$-3.78 |
| 2017 |
$-7.80 |
| 2016 |
$-10.73 |
| 2015 |
$-7.88 |
| 2014 |
$-0.10 |
| 2013 |
$-21.60 |
| 2012 |
$-11.60 |
| Affimed Quarterly EPS |
| 2024-09-30 |
$-1.03 |
| 2024-06-30 |
$-1.09 |
| 2024-03-31 |
$-1.38 |
| 2023-12-31 |
$-1.45 |
| 2023-09-30 |
$-1.74 |
| 2023-06-30 |
$-2.18 |
| 2023-03-31 |
$-2.30 |
| 2022-12-31 |
$-2.31 |
| 2022-09-30 |
$-1.11 |
| 2022-06-30 |
$-1.38 |
| 2022-03-31 |
$-1.57 |
| 2021-12-31 |
$-2.28 |
| 2021-09-30 |
$-1.65 |
| 2021-06-30 |
$-1.90 |
| 2021-03-31 |
$0.15 |
| 2020-12-31 |
$-1.93 |
| 2020-09-30 |
$-0.82 |
| 2020-06-30 |
$-1.76 |
| 2020-03-31 |
$-1.20 |
| 2019-12-31 |
$-2.14 |
| 2019-09-30 |
$-1.89 |
| 2019-06-30 |
$-1.91 |
| 2019-03-31 |
$0.34 |
| 2018-12-31 |
$1.82 |
| 2018-09-30 |
$-2.20 |
| 2018-06-30 |
$-1.55 |
| 2018-03-31 |
$-1.84 |
| 2017-12-31 |
$-1.68 |
| 2017-09-30 |
$-2.12 |
| 2017-06-30 |
$-1.98 |
| 2017-03-31 |
$-2.03 |
| 2016-12-31 |
$-1.80 |
| 2016-09-30 |
$-3.46 |
| 2016-06-30 |
$-2.71 |
| 2016-03-31 |
$-2.76 |
| 2015-12-31 |
$-2.10 |
| 2015-09-30 |
$-2.70 |
| 2015-06-30 |
$-2.10 |
| 2015-03-31 |
$-0.70 |
| 2014-12-31 |
$-2.40 |
| 2014-09-30 |
$26.90 |
| 2014-06-30 |
$12.30 |
| 2014-03-31 |
$-14.50 |
| 2013-09-30 |
$-534.60 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
